Progenics Pharmaceuticals, Inc. (PGNX), Halozyme Therapeutics, Inc. (HALO), Astex Pharmaceuticals, Inc. (ASTX): Three Humongous Health-Care Stocks This Week

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a few upcoming catalysts that hold the potential to make these insider purchases pay off in a short time frame. European approval for Roche‘s Herceptin using Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s recombinant human hyaluronidase, or rHuPH20, is expected soon. Baxter International Inc. (NYSE:BAX), Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s partner on HyQvia, expects to submit additional data to the FDA later this year to address questions raised in the complete response letter it received in 2012.

Looking good
All three of these stocks have looked pretty good lately. If the FDA advisory committee gives a thumbs-up on Relistor, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) could see the biggest upside through the end of the year. That’s not a given, though.

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) has a solid pipeline and good revenue coming in from Dacogen. Company management says next year could be tougher, with anticipated lower Dacogen sales in the U.S. Over the long run, Astex should do well.

Multiple possible catalysts could send Halozyme even higher in the months ahead. I like that the small company has strong partnerships with several larger companies.

There’s no guarantee that any of this week’s humongous health-care stocks will continue to sizzle like they have recently. However, my view is that investors who aren’t afraid of taking on risk should take a look at any or all of them. Hot stocks can sometimes get even hotter.

The article 3 Humongous Health-Care Stocks This Week originally appeared on Fool.com is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.